Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health
- PMID: 23720698
- PMCID: PMC3659962
- DOI: 10.3238/arztebl.2013.0319
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health
Abstract
Background: The incidence of malignant mesothelioma in Germany is about 20 cases per million persons per year. Its association with asbestos exposure, usually occupational, has been unequivocally demonstrated. Even though the industrial use of asbestos was forbidden many years ago, new cases of mesothelioma continue to appear because of the long latency of the disease (median, 50 years). Its diagnosis and treatment still present a major challenge for ambulatory and in-hospital care and will do so for years to come.
Methods: This article is based on a selective review of the literature, along with data from the German Mesothelioma Register.
Results: 1397 people died of mesothelioma in Germany in 2010. A plateau in the incidence of the disease is predicted between 2015 and 2030. Most mesotheliomas arise from the pleura. The histological subtype and the Karnofsky score are the main prognostic factors. Only limited data are now available to guide treatment with a combination of the available methods (chemotherapy, surgery, radiotherapy). The prognosis is still poor, with a median survival time of only 12 months. Symptom control and the preservation of the patient's quality of life are the main aspects of care for patients with mesothelioma.
Conclusion: The incidence of mesothelioma is not expected to drop in the next few years. The available treatments are chemotherapy, surgery, and radiotherapy. Specialized treatment centers now increasingly provide multimodal therapy for treatment of mesothelioma.
Figures
Comment in
-
Progress means change: reflections on two articles about pleural disease.Dtsch Arztebl Int. 2013 May;110(18):311-2. doi: 10.3238/arztebl.2013.0311. Dtsch Arztebl Int. 2013. PMID: 23720696 Free PMC article. No abstract available.
-
Surgical therapeutic options.Dtsch Arztebl Int. 2013 Sep;110(39):660. doi: 10.3238/arztebl.2013.0660a. Dtsch Arztebl Int. 2013. PMID: 24163708 Free PMC article. No abstract available.
-
In reply.Dtsch Arztebl Int. 2013 Sep;110(39):660. doi: 10.3238/arztebl.2013.0660b. Dtsch Arztebl Int. 2013. PMID: 24163709 Free PMC article. No abstract available.
Similar articles
-
Progress means change: reflections on two articles about pleural disease.Dtsch Arztebl Int. 2013 May;110(18):311-2. doi: 10.3238/arztebl.2013.0311. Dtsch Arztebl Int. 2013. PMID: 23720696 Free PMC article. No abstract available.
-
In reply.Dtsch Arztebl Int. 2013 Sep;110(39):660. doi: 10.3238/arztebl.2013.0660b. Dtsch Arztebl Int. 2013. PMID: 24163709 Free PMC article. No abstract available.
-
Surgical therapeutic options.Dtsch Arztebl Int. 2013 Sep;110(39):660. doi: 10.3238/arztebl.2013.0660a. Dtsch Arztebl Int. 2013. PMID: 24163708 Free PMC article. No abstract available.
-
[Value of thoracoscopy and talc pleurodesis in diagnosis and palliative treatment of malignant pleural mesothelioma].Praxis (Bern 1994). 1998 Mar 4;87(10):336-40. Praxis (Bern 1994). 1998. PMID: 9545840 Review. German.
-
Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues.Semin Respir Crit Care Med. 2015 Jun;36(3):334-46. doi: 10.1055/s-0035-1549449. Epub 2015 May 29. Semin Respir Crit Care Med. 2015. PMID: 26024342 Review.
Cited by
-
Case Report: A case of primary pericardial mesothelioma treated with multimodal combined therapy.Front Cardiovasc Med. 2024 Oct 7;11:1433668. doi: 10.3389/fcvm.2024.1433668. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39434853 Free PMC article.
-
PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.Cell Death Dis. 2019 Sep 27;10(10):725. doi: 10.1038/s41419-019-1916-3. Cell Death Dis. 2019. PMID: 31562297 Free PMC article.
-
CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion.Cancer Immunol Immunother. 2015 Aug;64(8):965-76. doi: 10.1007/s00262-015-1701-9. Epub 2015 May 6. Cancer Immunol Immunother. 2015. PMID: 25944005 Free PMC article.
-
Current causes of mesothelioma: how has the asbestos ban changed the perspective?Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Jun;167(2):99-108. doi: 10.5507/bp.2023.008. Epub 2023 Feb 20. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023. PMID: 36883200 Review.
-
Role of microRNAs in malignant mesothelioma.Cell Mol Life Sci. 2014 Aug;71(15):2865-78. doi: 10.1007/s00018-014-1584-5. Epub 2014 Feb 23. Cell Mol Life Sci. 2014. PMID: 24562347 Free PMC article. Review.
References
-
- Woitowitz H, Hillerdal G, Galvarezos A, Berghäuser K, Rödelsperger K, Jöckel K. Risiko und Einflussfaktoren des diffusen malignen Mesothelioms (DMM) Forschungsberichtsreihe FB 698. Bundesanstalt für Arbeitsschutz. 1993
-
- Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleura mesothelioma. Eur Repir J. 2010;35:479–495. - PubMed
-
- Selikoff I, Churg J, Hammond E. Relation between exposure to asbestos and mesothelioma. N Eng J Med. 1965;272:560–565. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical